INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$20.57
-0.54 (-2.56%)
As of Aug 8, 1:39 AM ET ·
Financial Highlights (FY 2026)
Revenue
347.70M
Net Income
229.22M
Gross Margin
74.8%
Profit Margin
65.9%
Rev Growth
+7.5%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 347.70M 323.50M 296.49M 325.02M
Gross Profit 260.08M 241.98M 199.68M 218.90M
Operating Income 138.42M 115.91M 108.77M 141.90M
Net Income 229.22M 191.94M 100.45M 107.69M
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Rev Growth +7.5% +7.5% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 132.74M 132.74M 569.66M 644.56M
Total Equity 604.17M 604.17M 1.17B 1.19B
D/E Ratio 0.22 0.22 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 150.21M 132.77M 161.71M 177.91M
Free Cash Flow 84.32M 106.96M